Guotai Haitong: Based on High Prosperity in Innovative Drug Industry, Strong Fundamentals of Listed Companies, and Low Valuations, Bullish on China's Innovative Drug Industry Development 国泰海通：基于创新药行业高景气度、上市公司基本面表现强劲及估值低位，看好中国创新药产业发展

Another brokerage research report is out. Guotai Junan is shouting "Optimistic about China's innovative drugs," citing the same old trio of "high prosperity," "strong fundamentals," and "low valuations." Reading it feels like an AI-generated hymn of praise—every word is correct, yet together they emit the scorched smell of "trading commissions." When has a brokerage's "optimism" ever been directly tied to the wallets of ordinary investors? The "low-valued heavyweight stocks" they recommend—are they hoping you’ll prop up the price, or do they truly believe those old-school pharma companies can transform into innovation engines overnight? As for the "biotech with BD potential in 2026," the vagueness of this prediction is hardly different from a fortune teller saying, "You’ll have good fortune next year." The only somewhat interesting point is the line about "bispecific antibody industry trends taking hold," but it’s buried under a pile of correct nonsense. Bispecific antibody technology does demonstrate greater potential than monoclonal antibodies based on clinical data, and several commendable players have emerged in this race among Chinese pharma companies. This is the technical conclusion that should be isolated and examined with a magnifying glass, rather than being wrapped up in the speculative narrative of "low valuations."

What’s truly interesting is another piece of data: margin financing balances in the two markets surged by 24 billion yuan in a single day. These leveraged funds swooped into the market like sharks smelling blood. Will this money flow into the innovative drug sector? Highly likely. But is this a "vote of confidence" for Guotai Junan’s report, or purely short-term speculation? Leveraged positions are known for coming in fast and leaving just as quickly. When market sentiment shifts, these leveraged "optimists" will run faster than anyone else. So, on one side, there’s the brokerage’s armchair industry narrative; on the other, the real and dangerous pulse of hot money. Together, they paint a picture of the innovative drug sector severely distorted by short-term sentiment and financial games.

Real industry trends, like bispecific antibodies, require sitting on cold benches and committing genuine long-term R&D investment. They involve failure after failure in clinical trials, with occasional breakthroughs. They shouldn’t be reduced to a checkbox in a research report, let alone become a concept hyped by speculative capital. When "optimism" becomes a cheap slogan, and when margin financing data resonates more than technological breakthroughs, we are probably still far from true industry prosperity. Don’t be fooled by that research report. Look at the flow of leveraged funds, and consider which companies are steadily advancing their clinical pipelines—that’s the real temperature of the world.

又一份券商研报出炉，国泰海通高喊“看好中国创新药”，理由无非是“高景气度”、“基本面强劲”、“估值低位”这老三样。读起来像AI生成的标准赞美诗，每个词都正确，但连在一起就散发着一股“交易佣金”的焦糊味。券商的“看好”，什么时候跟普通投资者的钱包直接挂钩过？他们推荐的“估值低位权重股”，是希望你去给他们抬轿子，还是真觉得那些老牌药企能一夜之间变成创新引擎？至于“2026年BD潜力的biotech”，这预测的模糊程度，跟算命先生说“你明年有财运”差不了太多。真正有点意思的是“双抗产业趋势已成”这一句，可惜被淹没在一堆正确的废话里。双抗技术确实在临床数据上展现了比单抗更好的潜力，中国药企在这个赛道也跑出了几个值得尊敬的玩家，这才是应该被拎出来，用放大镜审视的技术性结论，而不是被包裹在“估值低位”的投机叙事里。

真正有趣的数据是另一条：两市融资余额单日暴增240亿。这些杠杆资金像嗅到血腥味的鲨鱼一样扑向市场。这钱会去创新药板块吗？大概率。但这是对国泰海通报告的“投票”，还是纯粹的短期投机行为？融资盘的特性就是来得快，去得也快。当市场情绪反转，这些加了杠杆的“看好者”会比谁都跑得快。所以，一边是券商纸上谈兵的产业叙事，另一边是热钱真实而危险的脉搏。二者共同描绘出的，是一个被短期情绪和资金游戏严重扭曲的创新药板块图景。

真正的产业趋势，比如双抗，需要的是冷板凳和真金白银的长期研发投入，是临床试验中一个接一个的失败和偶尔的突破。它不应该被简化成研报里的一个勾选项，更不该成为游资炒作的概念。当“看好”成为一句廉价的口号，当融资数据比技术突破更牵动人心，我们离真正的产业繁荣，恐怕还很远。别被那份研报唬住，看看杠杆资金的流向，再想想哪些公司在实实在在地推进临床管线，那才是真实世界的温度。